TCP
GNCA

Tourbillon Capital Partners’s Genocea Biosciences, Inc. GNCA Stock Holding History

Tourbillon Capital Partners’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-87,361
Closed -$4.79M – 108
2015
Q3 		$4.79M Buy
87,361
+12,936
+17% +$1.28M 0.13% 84
2015
Q2 		$8.18M Buy
74,425
+24,375
+49% +$2.26M 0.18% 85
2015
Q1 		$4.75M Buy
+50,050
New +$3.53M 0.12% 69

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Tourbillon Capital Partners's GNCA Position: Q4 2015 in Review

Tourbillon Capital Partners sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2015, closing a stake of 87,361 shares — an estimated $4.79M sold.

Tourbillon Capital Partners first reported a position in GNCA in Q1 2015 and held it in 3 quarters. The position peaked at $8.18M in Q2 2015. 57 funds tracked by Wall St. Rank hold GNCA as of Q4 2015.

  • Tourbillon Capital Partners reported no remaining Genocea Biosciences, Inc. position as of Q4 2015 after selling out during the quarter.
  • Tourbillon Capital Partners sold 87,361 Genocea Biosciences, Inc. shares in Q4 2015, an estimated $4.79M.
  • Tourbillon Capital Partners first reported a position in Genocea Biosciences, Inc. in Q1 2015 and held it in 3 quarters.
  • Tourbillon Capital Partners's Genocea Biosciences, Inc. position peaked at $8.18M in Q2 2015.
  • 57 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2015.

Based on Tourbillon Capital Partners's 13F filing for Q4 2015, filed 16 Feb 2016.